Dextech Medical AB (XSAT:DEX)

Market Cap	188.56M +140.6%
Revenue (ttm)	3.07M -38.4%
Net Income	-5.63M
EPS	-0.30
Shares Out	18.49M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	13,233
Average Volume	3,761
Open	10.20
Previous Close	n/a
Day's Range	9.78 - 10.20
52-Week Range	3.62 - 14.40
Beta	1.42
RSI	43.62
Earnings Date	May 5, 2026

About Dextech Medical AB

Dextech Medical AB engages in the development of drug candidates with application in urological oncology, primarily prostate cancer in Sweden. The company’s lead candidate, OsteoDex, which has completed a phase IIb clinical trial for the treatment of bone metastases in castration-resistant prostate cancer, as well as in preclinical stage to treat breast and lung cancer, as well as multiple myeloma. The company is also developing SomaDex, a medication candidate that is based on an endogenous hormone, somatostatin, or the treatment of acromegaly,...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2004
• Employees: 1
• Stock Exchange: Spotlight Stock Market
• Ticker Symbol: DEX

Financial Performance

In fiscal year 2025, Dextech Medical AB's revenue was 3.22 million, a decrease of -40.15% compared to the previous year's 5.39 million. Losses were -4.84 million, 2.96% more than in 2024.